Shanghai Hile Bio-Technology Co., Ltd.

603718

CNE1000022T4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
8.34 ^CNY	+0.36%		-1.53%	-22.13%

29/04	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/04	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.

September 30, 2022

On September 30, 2022, Shandong Hile Biological Products Co., Ltd. closed the transaction.

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index	18/23/18	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Shanghai Zhizhuo Enterprise Management Consulting Co., Ltd. agreed to acquire Shanghai Caiyin Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for CNY 2 million.	12/23/12	CI
Shandong Sinder Technology Co., Ltd agreed to acquire Shandong Hile Biological Products Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 110 million.	12/23/12	CI
Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit	11/23/11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	30/22/30	CI
Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	30/22/30	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/21/29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/21/27	CI
WuXi Vaccines Inc. announced that it expects to receive $136 million in funding from Shanghai Hile Bio-Technology Co., Ltd., WuXi Biologics Inc.	13/21/13	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it has received CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	29/21/29	CI
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A.	29/21/29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	23/21/23	CI
WuXi Biologics Cayman : , Shanghai Hile to Restructure Vaccine JV	02/21/02	MT
Shanghai Hile Bio-Technology Co., Ltd. intends to acquire 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A. for CNY 56 million.	17/21/17	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	15/21/15	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	27/20/27	CI

Chart Shanghai Hile Bio-Technology Co., Ltd.

Duration

Period

Chart Shanghai Hile Bio-Technology Co., Ltd.

More charts

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.

Sector

Pharmaceuticals

Calendar

23/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD.	-22.13%	756M
ZOETIS INC.	-14.47%	76.62B
ELANCO ANIMAL HEALTH INCORPORATED	+14.80%	8.4B
BLUESTAR ADISSEO COMPANY	+25.88%	3.76B
VIMIAN GROUP AB	+18.24%	1.65B
JINYU BIO-TECHNOLOGY CO., LTD.	-8.82%	1.53B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-22.51%	1.3B
VETOQUINOL SA	-3.32%	1.25B
WUHAN KEQIAN BIOLOGY CO.,LTD	-10.11%	1.19B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	+4.27%	1.1B

Veterinary Drugs

Shanghai Hile Bio-Technology Co., Ltd.

Equities

603718

CNE1000022T4

Pharmaceuticals

Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Chart Shanghai Hile Bio-Technology Co., Ltd.

Company Profile

Income Statement Evolution

Sector Veterinary Drugs